High-Intensity Interval Training Is Feasible in Women at High Risk for Breast Cancer.


Journal

Medicine and science in sports and exercise
ISSN: 1530-0315
Titre abrégé: Med Sci Sports Exerc
Pays: United States
ID NLM: 8005433

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 4 7 2019
medline: 2 6 2020
entrez: 4 7 2019
Statut: ppublish

Résumé

This trial aimed to demonstrate the feasibility of high-intensity interval training (HIIT) in postmenopausal, overweight/obese women at high risk of invasive breast cancer and to explore HIIT on changes in cardiorespiratory fitness (CRF), body weight, and body mass index (BMI) compared with moderate-intensity continuous training (MICT) and usual care (UC). Forty-four women were randomized to HIIT, MICT, or UC for a 12-wk, thrice weekly, supervised exercise intervention. HIIT included a 5-min warm-up at 50%-70% HRpeak, four cycles of 4 min at 90%-100% HRpeak, followed by 3 min at 50%-70% HRpeak. MICT consisted of 41 min at 60%-70% HRpeak. Feasibility was assessed by consent, adherence, compliance, and retention rates. CRF, body weight, and BMI were measured at baseline and end of study. Repeated-measures linear mixed models were used to assess within- and between-group differences. Average age was 63.9 ± 8.8 yr. BMI was 30.9 ± 5.7 kg·m. Participants completed 90% and 89% of HIIT and MICT workouts, respectively, with 100% compliance to the exercise prescriptions. No serious adverse events were reported. Compared with MICT and UC, HIIT exhibited improvements in change in treadmill time (101 s greater than MICT, and 125 s greater than UC, respectively, P < 0.001). Compared with UC, HIIT exhibited improvement in changes in absolute and relative V˙O2peak (a 0.15-L·min increase, P = 0.005, and a 2.3-mL·kg⋅min increase, P = 0.004). There were no significant differences between groups for body weight or BMI (P > 0.05). HIIT is feasible, safe, and seems to promote greater improvements in CRF compared with MICT and UC in women at high risk for breast cancer.

Identifiants

pubmed: 31269007
doi: 10.1249/MSS.0000000000002048
pmc: PMC7028472
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2193-2200

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Références

J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8
pubmed: 10491430
Circulation. 2007 Jun 19;115(24):3086-94
pubmed: 17548726
Am Heart J. 2009 Dec;158(6):1031-7
pubmed: 19958872
J Cancer Surviv. 2016 Jun;10(3):467-79
pubmed: 26482384
Tumour Biol. 2016 Nov;37(11):14363-14380
pubmed: 27623943
Res Sports Med. 2009;17(3):156-70
pubmed: 19731176
Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1893-902
pubmed: 25114017
Br J Sports Med. 2014 Aug;48(16):1227-34
pubmed: 24144531
Women Health. 2000;30(4):61-76
pubmed: 10983610
JAMA. 1996 Jul 17;276(3):205-10
pubmed: 8667564
Circulation. 2008 Jul 22;118(4):346-54
pubmed: 18606913
Diabetologia. 2016 Jan;59(1):56-66
pubmed: 26350611
Annu Rev Med. 2015;66:297-309
pubmed: 25587653
J Cardiopulm Rehabil Prev. 2011 Nov-Dec;31(6):378-85
pubmed: 21946419
Clin Colorectal Cancer. 2018 Jun;17(2):e269-e279
pubmed: 29397328
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
pubmed: 2593165
Arch Intern Med. 2010 Oct 25;170(19):1758-64
pubmed: 20975025
Can J Appl Sport Sci. 1985 Sep;10(3):141-6
pubmed: 4053261
Med Sci Sports Exerc. 2009 Apr;41(4):742-8
pubmed: 19276861
Diabetologia. 2017 Jan;60(1):7-23
pubmed: 27681241
Epidemiology. 2007 Jan;18(1):137-57
pubmed: 17130685
Am J Clin Nutr. 1987 Jan;45(1 Suppl):328-35
pubmed: 3799523
J Sports Med Phys Fitness. 2012 Jun;52(3):255-62
pubmed: 22648463
JAMA Oncol. 2015 May;1(2):231-7
pubmed: 26181028
JAMA. 2003 Sep 10;290(10):1331-6
pubmed: 12966124
Eur J Cardiovasc Prev Rehabil. 2004 Jun;11(3):216-22
pubmed: 15179103
JAMA Netw Open. 2018 Oct 5;1(6):e183605
pubmed: 30646252
Cell Res. 2007 Apr;17(4):280-2
pubmed: 17404599
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):236-43
pubmed: 17301255
PLoS One. 2015 Oct 21;10(10):e0138853
pubmed: 26489022
Am J Clin Nutr. 2002 May;75(5):818-26
pubmed: 11976154
J Am Heart Assoc. 2012 Aug;1(4):e001354
pubmed: 23130161
Int J Behav Nutr Phys Act. 2012 Jun 22;9:78
pubmed: 22726453

Auteurs

Adriana M Coletta (AM)

Cancer Control and Population Sciences Program, Huntsman Cancer Institute, Salt Lake City, UT.
Department of Health, Kinesiology, and Recreation, The University of Utah, Salt Lake City, UT.

Abenaa M Brewster (AM)

Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.

Minxing Chen (M)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Yisheng Li (Y)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Therese B Bevers (TB)

Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.

Karen Basen-Engquist (K)

Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX.

Susan C Gilchrist (SC)

Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH